Max Hodak, the co-founder of Neuralink, has turned his attention to a new venture that has raised eyebrows in the tech community. While he insists there are no hard feelings towards his former company, his recent financial moves suggest otherwise.

Hodak has successfully raised $47 million for a fresh brain interface project called Science Corp. Furthermore, he has personally backed Synchron, a direct competitor to Neuralink. In a blog update, Hodak expressed his enthusiasm for Synchron’s mission and his commitment to supporting their journey in any capacity he can.

What sets Synchron apart from Neuralink is their innovative approach to accessing the brain through blood vessels rather than implanting a chip directly into the skull. The company has already launched human trials and has reported remarkable achievements, including enabling a man with ALS to tweet using their technology.

In contrast, Neuralink has not yet embarked on human trials, despite Elon Musk’s earlier announcements about starting chip implants back in 2022 without providing a clear timeline. Hodak’s engagement with Synchron adds to the mounting challenges Neuralink faces, sparking concerns about its trajectory.

As competition heats up between Neuralink and its rivals, it remains uncertain which company will emerge as the leader in brain-computer interface technology. Hodak’s calculated investments could play a significant role in shaping the future of this groundbreaking field.

For a deeper look into the rivalry between Neuralink and its competitors, be sure to check out the detailed article from Insider. Additionally, former employees have shared intriguing anecdotes about their experiences working under Elon Musk’s direction at Neuralink.

The race to transform brain-computer interfaces is gaining momentum, and Hodak’s involvement in these pivotal advancements is certainly one to watch.